Color profile: Disabled Composite Default screen
CONSULTATIONS IN GASTROENTEROLOGY 100
100
95
95
75
75
25
25
5
5
0
0
Primary adenocarcinoma in an enterocutaneous fistula associated with Crohn’s disease Luis T Ying MD, David J Hurlbut MD FRCPC, William T Depew MD FRCPC, Alexander H Boag MD FRCPC, Kenneth Taguchi MD FRCS
100
LT Ying, DJ Hurlbut, WT Depew, AH Boag, K Taguchi. Primary adenocarcinoma in an enterocutaneous fistula associated with Crohn’s disease. Can J Gastroenterol 1998;12(4):265-269. Increasing numbers of intestinal adenocarcinomas in patients with Crohn’s disease have been reported, but the strength of this association still needs to be elucidated. Adenocarcinoma has also been documented in different types of fistulous tracts associated with Crohn’s disease. The first case of well-differentiated mucinous adenocarcinoma involving only enterocutaneous fistulae is reported in a patient with long-standing Crohn’s disease complicated by persistent abdominal wall fistulous tracts. The malignant lesion arose from neoplastic transformation of columnar epithelium lining portions of the fistulae occurring as a result of either re-epithelialization of these inflammatory tracts or mural implantation of mucosal tissue secondary to prior ulceration. The patient has remained disease-free eight years after surgical resection of the tumour. Even though intestinal carcinoma is not as strongly associated with Crohn’s disease as with ulcerative colitis, intestinal carcinoma should be considered in the setting of long-standing disease, previous intestinal exclusion surgeries and complications such as enterocutaneous or other types of fistulous tracts. The prognosis of such patients may be excellent with early diagnosis and treatment.
Adénocarcinome primaire dans une fistule entérocutanée associée à la maladie de Crohn RÉSUMÉ : Le nombre d’adénocarcinomes intestinaux est en hausse chez les patients atteints de maladie de Crohn, mais la nature de ce lien doit être éclaircie. L’adénocarcinome a aussi été documenté dans différents types de fistules associées à la maladie de Crohn. Le premier cas d’adénocarcinome mucineux bien différencié mettant en cause une fistule entérocutanée seulement est signalé chez un patient souffrant de longue date d’une maladie de Crohn compliquée de fistules abdominales persistantes. La lésion cancéreuse tire son origine de la transformation néoplasique de l’épithélium cylindrique tapissant certaines portions des fistules, par suite, soit d’une ré-épithélialisation des ces canaux inflammatoires, soit de l’implantation murale de tissus muqueux secondaire à une ulcération. Le patient est resté bien pendant huit ans suivant la résection chirurgicale de la tumeur. Bien que le cancer de l’intestin ne soit pas associé aussi souvent à la maladie de Crohn qu’à la colite ulcéreuse, il faut songer à ce diagnostic dans le contexte d’une maladie chronique, d’antécédents de chirurgies intestinales et de complications, telles fistules entérocutanées ou autres. Le pronostic peut être excellent chez ces patients si le diagnostic et le traitement se font sans délai.
95
75
25
5
Key Words: Adenocarcinoma, Crohn’s disease, Enterocutaneous fistulae, Fistulous tracts
This paper was a winning entry in the ‘Consultations in Gastroenterology’ Case Study Competition that was initiated and funded with the generous sponsorship of Astra Canada and is endorsed by the Canadian Association of Gastroenterology Departments of Medicine, Pathology and Surgery, Queen’s University, Kingston, Ontario Correspondence and reprints: Dr William T Depew, Hotel Dieu Hospital, 166 Brock Street, Kingston, Ontario K7L 5G2. Telephone 613-544-3310, fax 613-544-3114, e-mail
[email protected]
100
95
75
25
5
0
0
Can J Gastroenterol Vol 12 No 4 May/June 1998
265 1
G:\GASTRO\1998\12#4\ying.vp Tue Jun 02 14:57:18 1998
Ying et al
C
rohn’s disease was first described as a distinct clinical and pathological entity in 1932 (1). The first reports of Crohn’s disease patients who subsequently developed cancer of the large or small intestine were published in 1948 and 1956, respectively (2,3). Since then, the number of reported cases has increased significantly, but it is still unclear whether patients with Crohn’s disease are at higher risk of developing intestinal malignancies. There have also been reported cases of adenocarcinoma in enterocolonic, enterovesicular, enterovesiculocutaneous, rectovaginal and perineal fistulae associated with Crohn’s disease (4-8). To date only five cases of adenocarcinoma in enterocutaneous fistulae have been reported, but in all these cases the carcinoma involved both the fistulous tract as well as segments of either contiguous small or large bowel (5,8,9). In this paper we describe the first case of mucinous adenocarcinoma that originated from and remained confined to an enterocutaneous fistula in a patient with Crohn’s disease. CASE PRESENTATION A 55-year-old male was initially diagnosed with Crohn’s ileitis in 1965, at age 23. He underwent segmental ileal resection in 1970 and 1972 to treat active disease refractory to medical therapy. A total of 62 cm of terminal ileum was removed. In 1972, he developed two anterior abdominal wall fistulae with persistent mild drainage of a serous material. One was located in the midline, just caudal to the umbilicus, and the other in the right peri-umbilical area. The drainage from these fistulae fluctuated in concert with his Crohn’s disease activity. Maintenance therapy with sulfasalazine provided acceptable control of the disease. By 1974, one of the fistulae had healed, but in that year he developed a third fistula located in the left upper abdominal quadrant, from which there was draining of fecal and purulent material along with passage of gas. A fistulogram revealed a connection to the small bowel. The drainage settled spontaneously and the patient declined any further investigative or therapeutic efforts. He remained on sulfasalazine thereafter. A therapeutic trial with metronidazole to close the fistulae in 1981 was discontinued soon after initiation due to adverse effects. For most of the 1980s, the patient’s clinical course was relatively unremarkable with only infrequent mild symptoms that occurred whenever he was noncompliant with his medication. In 1989 the patient experienced a severe exacerbation of his disease, with worsening diarrhea, intense abdominal cramps, fever, chills and an approximately 8 kg weight loss. Over a period of three months he also developed an inflammatory lesion on his anterior abdominal wall at the site of one of his fistulae, from which profuse drainage of fecal and purulent material occurred through six fistulous tracts (Figure 1). Barium enema and fistulogram showed a small enterocolonic fistula between the terminal ileum and sigmoid colon, as well as multiple interconnecting sinus tracts within the inflammatory abdominal wall mass that communicated with the enterocolonic fistula (Figure 2). Small bowel follow-through did not reveal obstruction. Treatments with
266
Figure 1) Anterior abdominal wall inflammatory mass lesion, with mul-
tiple draining fistulous tracts. Location is midline and caudal to the umbilicus
metronidazole and azathioprine were attempted for one month, but these were discontinued due to gastrointestinal adverse effects and sepsis, respectively. The patient’s systemic and gastrointestinal symptoms gradually improved with sulfasalazine, but the draining abdominal wall lesion did not change. Surgery to excise the inflammatory mass and tracts, as well as the involved segment of small bowel and the enterocutaneous fistula, was preformed. Pathological examination of the surgical specimen revealed well-differentiated mucinous adenocarcinoma within and around the fistulous tracts, primarily within the abdominal wall mass (Figure 3). No small bowel mucosal origin for adenocarcinoma was identified. Multiple fistulous tracts were lined by columnar epithelium with areas of neoplastic transition to infiltrating adenocarcinoma within subserosal and abdominal wall tissues. All four mesenteric lymph nodes were negative for adenocarcinoma. Ancillary resection of a smaller nondraining inflammatory mass in the left upper abdominal quadrant did not show any malignant lesion. At eight years after surgery, the patient is tumour-free and has no evidence of fistula recurrence. His Crohn’s disease has been quiescent. Can J Gastroenterol Vol 12 No 4 May/June 1998
Primary adenocarcinoma associated with Crohns disease
Figure 2) Above Fistulogram lateral film. Arrowhead identifies fistu-
logram catheter containing contrast. Arrows identify multiple fistulous tracts within abdominal wall. Right Fistulogram supine delayed film. Black arrowhead identifies fistulogram catheter containing contrast. Arrows identify loop of large bowel communicating with fistulous tracts
Figure 3) A, B Whole mount sections of resected small bowel wall showing distorted mural architecture with inflammation, fibrosis and a complex arrangement of fistulous tracts (arrows). B Fibrotic subserosal tissue adherent to the abdominal wall reveals transition to invasive mucinous adenocarcinoma (arrows),which widely infiltrates skin(C, arrow). D, E Malignant glands are distended with abundant mucin and lined by atypical columnar epithelial cells DISCUSSION Since Crohn’s disease was initially described in 1932, increasing numbers of cases of adenocarcinoma of the large and small bowel in patients with this disease have been reported. The extent of the association between Crohn’s disease and intestinal adenocarcinoma is still not entirely clear. The relative risk of colorectal cancer in patients with Crohn’s disease has been calculated to range from 4.3 to 26.6 (1012), and estimates of the relative risk of small bowel adenocarcinoma have ranged from six to 320 times that in a normal population (12-15). Five large population-based epidemiological studies involving 3747 patients with Crohn’s disease documented 21 cases of colorectal and seven cases of small bowel cancer, with relative risks ranging from 0.89 to 2.5 for colorectal malignancies and up to 50 for small bowel Can J Gastroenterol Vol 12 No 4 May/June 1998
malignancies (16-21). Two of these population-based studies involving 468 patients did not document any case of small bowel cancer in the cohort of Crohn’s disease patients (17,18). The inconsistency in the relative risk of colorectal adenocarcinoma in Crohn’s disease may be due, in part, to referral bias in studies originating from tertiary care referral centres, which can generate an overestimation of this association. The relative risk of small bowel malignancy seems to be significantly higher in Crohn’s disease patients than in the general population, but caution must be applied to the interpretation of these data. Small bowel cancer is not a common condition; therefore, the publication of a relatively small number of cases in patients with Crohn’s disease may result in high relative risk estimates. In this paper we report the first case of adenocarcinoma 267
Color profile: Disabled Composite Default screen
Ying et al 100
95
100
TABLE 1 Summary of clinical data on six patients with adenocarcinoma of enterocutaneous fistulae associated with Crohn’s disease Duration of Age disease Areas of (years)/sex (years) disease
75
25
75
Fistula
Etiology of fistula
Areas of tumour involvement
Treatment of tumour
Clinical course
Case 1
70/F
38
Ileum
Enterovesiculocutaneous
Post-pig-tail catheter
Terminal ileum, ascending colon, fistula, peri-umbilical and perivesicular soft tissue
Surgery
No recurrence at 12 month F/U
Case 2
86/F
>10
N/A
Enterocutaneous
N/A
Excluded small bowel
N/A
N/A
Case 3
N/A
>10
N/A
Enterovesiculocutaneous
N/A
N/A
N/A
N/A
Case 4
50/F
30
Ileum/ colon
Enterocutaneous
Postsurgery
Fistulous tract and involved sigmoid colon
Surgery and radiation
Died two years after diagnosis
Case 5
30/M
“Long history”
Colon
Enterocutaneous
Postsurgery
Fistulous tract and colon
Surgery
Died six months after surgeries from renal amyloidosis
Current case
47/M
24
Ileum
Enterocutaneous
Postsurgery
Fistulous tract
Surgery
No recurrence at eight years F/U
5
0
95
25
5
0
F Female; F/U Follow-up; M Male; NA Not available
100
95
75
25
5
therapeutic modality in the treatment of Crohn’s disease in recent decades, the proportion of carcinoma in excluded small intestine in Crohn’s disease has fallen dramatically (8,24). In contrast to the patients in the five reports of adenocarcinoma of enterocutaneous fistulae associated with Crohn’s disease, our patient had a malignant lesion confined to the fistulous tracts, with no direct involvement of the communicating segment of small bowel. Adenocarcinoma most likely arose from neoplastic transformation of columnar epithelial lining portions of the fistulae occurring as a result of either re-epithelialization of inflammatory tracts from the small bowel mucosa or mural implantation of viable mucosal tissue secondary to prior ulceration. Chronic fistulous tracts in Crohn’s disease can re-epithelialize, which would preclude permanent healing (25). The absence of small bowel mucosal and mural involvement supports the negative mesenteric node status observed.
involving enterocutaneous fistulae only, in a patient with long-standing Crohn’s disease complicated by persistent abdominal wall fistulous tracts. Our review of the literature revealed only two cases of carcinoma of enterovesiculocutaneous fistulae (5,8) and three similar cases involving enterocutaneous fistulae in patients with Crohn’s disease (8,9) (Table 1). When he was diagnosed with adenocarcinoma, our patient had a 24-year history of Crohn’s disease and a 17-year history of persistent abdominal wall enterocutaneous fistulae. This time lag for the development of a malignant lesion is consistent with that in previously reported cases. Except for one case – which did not include details regarding the duration of Crohn’s disease before the diagnosis of the carcinomatous fistula – all lesions occurred more than 10 years after the initial diagnosis. In one case, the patient had Crohn’s disease for 38 years. For small bowel adenocarcinoma, Hawker et al (22) documented a mean delay of 19.2 years, with a range of up to 47 years. There is no uniformity in the anatomical location of disease among the reported cases. Including this case, two patients had ileitis, one had ileocolitis and one had colitis primarily. In the previously reported five cases, the malignant lesion was not confined to the enterocutaneous fistula; it also involved the surrounding inflamed segments of bowel. These observations support the notion that intestinal cancers in Crohn’s disease occur at sites of intestinal involvement (23). In one case, the tumour originated from an excluded segment of small intestine (8). It has been postulated that bypass or defunction with bacterial stasis in such segments has a carcinogenic effect (24). There have been many published reports of intestinal carcinoma arising in surgically bypassed bowel (22,24), but the most important contributing factor to carcinoma development in patients with excluded intestine may be the long duration of Crohn’s disease, rather than the excluded bowel (8,24). As intestinal exclusion surgeries have become increasingly infrequent as a
CONCLUSIONS Even though intestinal carcinoma is not as strongly associated with Crohn’s disease as with ulcerative colitis, intestinal carcinoma must be considered in the setting of longstanding disease, previous intestinal exclusion surgeries and complications such as enterocutaneous or other types of fistulous tracts. If accurate diagnosis is made without delay, the prognosis of these patients after appropriate treatment may be excellent.
100
95
REFERENCES 1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological and clinical entity. JAMA 1932;99:1323-9. 2. Warren S, Sommers SC. Cicatrizing enteritis (regional ileitis) as a pathologic entity: an analysis of 120 cases. Am J Pathol 1948;24:475-501. 3. Ginzburg L, Schneider KM, Dreizin DH, Levinson C. Carcinoma of the jejunum occurring in a case of regional enteritis. Surgery 1956;39:347-51.
0
75
25
5
0
268
Can J Gastroenterol Vol 12 No 4 May/June 1998 4
G:\GASTRO\1998\12#4\ying.vp Tue Jun 02 14:57:18 1998
Color profile: Disabled Composite Default screen
Primary adenocarcinoma associated with Crohn’s disease 100
95
75
25
5
0
100
4. Greenstein AJ, Janovitz HD. Cancer in Crohn’s disease. The danger of a by-passed loop. Am J Gastroenterol 1975;64:122-4. 5. Schoenfeld PS, Butler JA, Denobile J. Adenocarcinoma in an enterovesiculocutaneous fistula. Am J Gastroenterol 1996;91:608-9. 6. Buchmann P, Allan RN, Thompson H, Alexander-Williams J. Carcinoma in a rectovaginal fistula in a patient with Crohn’s disease. Am J Surg 1980;140:462-3. 7. Chaikhouni A, Regueyra FI, Stevens JR. Adenocarcinoma in perineal fistulas of Crohn’s disease. Dis Colon Rectum 1981;24:639-43. 8. Ribeiro MB, Greenstein AJ, Heimann TM, Yamazaki Y, Aufses AH Jr. Adenocarcinoma of the small intestine in Crohn’s disease. Surg Gynecol Obstet 1991;173:343-9. 9. Lightdale CJ, Sternberg SS, Posner G, Sherlock P. Carcinoma complicating Crohn’s disease. Report of seven cases and review of the literature. Am J Med 1975;59:262-8. 10. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn’s disease and cancer. N Engl J Med 1973;289:1099-102. 11. Gyde SN, Prior P, MacCartney JC, et al. Malignancy in Crohn’s disease. Gut 1980;21:1024-9. 12. Greenstein AJ, Sachar D, Smith H, et al. A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer 1981;48:2742-5. 13. Hoffman JP, Taft DA, Wheelis RF, Walker JH. Adenocarcinoma in regional enteritis of the small intestine. Arch Surg 1977;112:606-11. 14. Korelitz B. Carcinoma of the intestinal tract in Crohn’s disease: results of a survey conducted by National Foundation for Ileitis and Colitis. Am J Gastroenterol 1983;78:44-6. (Edit) 15. Fresko D, Lazarus DD, Dotan J, Reingold M. Early presentation of carcinoma of the small bowel in Crohn’s disease (Crohn’s carcinoma):
16. 17. 18. 19. 20. 21. 22. 23. 24. 25.
case reports and review of the literature. Gastroenterology 1982;82:783-9. Ekbom A, Helmick C, Zack M, Adami H-O. Increased risk of large bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990;336:357-9. Gollop JH, Phillips SF, Melton JH III, Zinsmeister AR. Epidemiologic aspects of Crohn’s disease: a population-based study in Olmsted County, Minnesota, 1943-1982. Gut 1988;29:49-56. Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn’s disease. A population study in Central Israel. Scand J Gastroenterol 1989;24:346-50. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993;105:1716-23. Persson P-G, Karlen P, Bernell O, et al. Crohn’s disease and cancer: a population-based cohort study. Gastroenterology 1994;107:1675-9. Ekbom A, Helmick C, Zack M, Adami H-O. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67:2015-9. Hawker PC, Gyde SN, Thompson H, Allan RN. Adenocarcinoma of the small intestine complicating Crohn’s disease. Gut 1982;23:188-93. Michelassi F, Testa G, Pomidor WJ, et al. Adenocarcinoma complicating Crohn’s disease. Dis Colon Rectum 1993;36:654-61. Greenstein AJ, Sachar D, Pucillo A, et al. Cancer in Crohn’s disease after diversionary surgery: A report of seven carcinomas occurring in excluded small bowel. Am J Surg 1978;135:86-90. Lewin KJ, Riddell RH, Weinstein WM. Gastrointestinal Pathology and its Clinical Implications. New York: Igaku-Shoin, 1992:887.
95
75
25
5
0
100
100
95
95
75
75
25
25
5
5
0
0
Can J Gastroenterol Vol 12 No 4 May/June 1998
269 5
G:\GASTRO\1998\12#4\ying.vp Tue Jun 02 14:57:18 1998
MEDIATORS of
INFLAMMATION
The Scientific World Journal Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Gastroenterology Research and Practice Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Journal of
Hindawi Publishing Corporation http://www.hindawi.com
Diabetes Research Volume 2014
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
International Journal of
Journal of
Endocrinology
Immunology Research Hindawi Publishing Corporation http://www.hindawi.com
Disease Markers
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Volume 2014
Submit your manuscripts at http://www.hindawi.com BioMed Research International
PPAR Research Hindawi Publishing Corporation http://www.hindawi.com
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Volume 2014
Journal of
Obesity
Journal of
Ophthalmology Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Evidence-Based Complementary and Alternative Medicine
Stem Cells International Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Journal of
Oncology Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Parkinson’s Disease
Computational and Mathematical Methods in Medicine Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
AIDS
Behavioural Neurology Hindawi Publishing Corporation http://www.hindawi.com
Research and Treatment Volume 2014
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
Oxidative Medicine and Cellular Longevity Hindawi Publishing Corporation http://www.hindawi.com
Volume 2014
